Roche Expands Automated Mass Spectrometry Portfolio with CE Mark Approval for Antibiotic Drug Monitoring, Delivering the Industry’s Broadest IVD Menu Roche announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring.…
TUKYSA Added to First-Line Maintenance Therapy Boosts Median Progression-Free Survival by More Than 8 Months in HER2+ Metastatic Breast Cancer Patients Pfizer Inc. today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as…
Roche’s Giredestrant Lowers Risk of Invasive Disease Recurrence or Death by 30% in Early-Stage ER-Positive Breast Cancer Roche announced today positive data from the phase III lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people…
AskBio’s AB-1005 and AB-1002 Granted Pioneering Regenerative Medicine Product Designation in Japan AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)…
Novartis’ Ianalumab Provides Sustained Disease Control in Immune Thrombocytopenia Patients with Just Four Monthly Doses Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1-3.…
Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the…
Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by the IAEA and co-sponsored by the World Health Organization (WHO)…
Roche Highlights Lunsumio Data Demonstrating Promise in Earlier Treatment Settings for Both Indolent and Aggressive Lymphomas Roche announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different types of lymphoma, presented…
Most Nations Advance Toward Universal Health Coverage, Yet Significant Obstacles Persist, Finds WHO–World Bank Report Since 2000, most countries – across all income levels and regions – have made concurrent progress in expanding health service coverage and reducing the financial…
Advancing Transplant Innovation with First-of-Its-Kind Insights from Organ Donor-Derived Bone Marrow Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical data at the at the 66th American Society of Hematology…
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols, S.A. the global leader in plasma-derived therapies and healthcare innovation.…
Bristol Myers Squibb’s Breyanzi Becomes First and Only CAR T Cell Therapy Approved by FDA for Relapsed or Refractory Marginal Zone Lymphoma Breyanzi® CD19-directed chimeric antigen receptor (CAR) T cell therapy—for the treatment of adult patients with relapsed or refractory…
